Altmetrics
Downloads
182
Views
62
Comments
0
A peer-reviewed article of this preprint also exists.
supplementary.pdf (1.44MB )
This version is not peer-reviewed
Submitted:
26 April 2023
Posted:
28 April 2023
You are already at the latest version
Database Type | Count | List |
---|---|---|
English databases | 6 | MEDLINE (via PubMed), ProQuest, Cochrane Register of Controlled Trials (CENTRAL), Emcare (via Ovid), Cumulative Index to Nursing & Allied Health Literature (CINAHL plus, via EBSCO), and Web of Science (exclude MEDLINE & KCI). |
Chinese databases | 2 | Chinese National Knowledge Infrastructure Database (CNKI) and Wanfang. |
Korean databases | 3 | Korean Journal Database (KCI, via Web of Science), Research Information Service System (RISS), and ScienceON. |
Japanese databases | 2 | CiNii and J-Stage. |
Summary Characteristics | N (% total) | |||
---|---|---|---|---|
All included articles | 98 (100%) | |||
Publication Years | ||||
2018-2022 | 18 (18.37%) | |||
2013-2017 | 26 (26.53%) | |||
2008-2012 | 18 (18.37%) | |||
2003-2007 | 21 (21.43%) | |||
1998-2002 | 15 (15.31%) | |||
Country | ||||
United States of America (USA) | 29 (29.59%) | |||
Japan | 22 (22.45%) | |||
South Korea | 15 (15.31%) | |||
Egypt | 11 (11.22%) | |||
Hungary | 7 (7.14%) | |||
Others | 15 (14.29%) | |||
Language | ||||
English | 81 (82.65%) | |||
Japanese | 11 (11.22%) | |||
Korean | 6 (6.12%) | |||
Publication Type | ||||
Full paper | 85 (86.73%) | |||
Abstract | 8 (8.16%) | |||
Book Chapter | 2 (2.04%) | |||
Short communication | 1 (1.02%) | |||
Study protocol | 1 (1.02%) | |||
Thesis | 1 (1.02%) |
Summary Characteristics | N (% total) | |||||
---|---|---|---|---|---|---|
All included articles | 98 (100%) | |||||
Study Design | ||||||
Preclinical | 56 (57.14%) | |||||
Animal | 25 (25.51%) | |||||
Animal + Cell | 6 (6.12%) | |||||
Animal + Cell + Chemical | 3 (3.06%) | |||||
Cell | 19 (19.39%) | |||||
Cell + Chemical | 2 (2.04%) | |||||
Chemical | 1 (1.02%) | |||||
Clinical | 42 (42.86%) | |||||
Interventional | ||||||
Randomised controlled trial | 21 (21.43%) | |||||
Non-randomised controlled trial | 1 (1.02%) | |||||
Before and after study | 7 (7.14%) | |||||
Observational | ||||||
Descriptive cross-sectional study | 1 (1.02%) | |||||
Case series | 4 (4.08%) | |||||
Case report | 8 (8.16%) | |||||
Translational Stage | ||||||
T0 – Basic biomedical research | 56 (57.14%) | |||||
T1 – Translation to humans | 38 (38.78%) | |||||
T2 – Translation to patients | 4 (4.08%) |
Summary Characteristics | N (% total) | ||||
---|---|---|---|---|---|
All included articles | 98 (100%) | ||||
Commercial Source of RBAC | |||||
Daiwa Pharmaceutical Co. Ltd. | 85 (86.73%) | ||||
Erom Co. Ltd. | 8 (8.16%) | ||||
STR Biotech Co. Ltd. | 5 (5.10%) | ||||
Funding Sources | |||||
Not Disclosed | 50 (51.02%) | ||||
Disclosed * | 48 (48.98%) | ||||
Commercial – Daiwa | 26 (26.53%) | ||||
Public | 17 (17.35%) | ||||
Commercial – Daiwa (Product Only) | 8 (8.16%) | ||||
Private / Nonprofit | 6 (6.12%) | ||||
Commercial – Erom | 5 (5.10%) | ||||
Commercial – Others | 2 (2.04%) |
Publishing | TWC | Article | Clinical | Preclinical | |||||
---|---|---|---|---|---|---|---|---|---|
# | Author | Period | Count (% Total) | Intervention | Observation | Animal | In Vitro | Chemical | |
1 | Ghoneum, Mamdooh | 1998 - 2021 | 30.00 | 30 (30.61%) | 26.7% | - | 30.0% | 53.3% | - |
2 | Badr El-Din, Nariman K. | 2008 - 2020 | 7.64 | 9 (9.18%) | - | - | 88.9% | 11.1% | - |
3 | Gollapudi, Sastry | 2003 - 2011 | 6.00 | 6 (6.12%) | - | - | - | 100% | - |
3 | Hajtó, Tibor | 2013 - 2018 | 6.00 | 6 (6.12%) | - | 100% | - | - | - |
5 | Maeda, Hiroaki | 2000 - 2004 | 5.36 | 7 (7.14%) | 14.3% | - | 57.1% | 14.3% | 28.6% |
6 | Egashira, Yukari | 2001 - 2017 | 4.50 | 6 (6.12%) | - | - | 83.3% | 16.7% | - |
7 | Lewis, John E. | 2012 - 2020 | 4.00 | 4 (4.08%) | 100% | - | - | - | - |
8 | Hong, Seong Gil | 2005 - 2022 | 3.75 | 6 (6.12%) | 16.7% | - | 66.7% | 50.0% | - |
Publishing | No. | TWC | Article | ||||
---|---|---|---|---|---|---|---|
# | Institution | Country | Type | Period | Authors | Authors | Count (% Total) |
1 | Charles Drew University of Medicine and Science | USA | Academic | 1998 - 2021 | 6 | 35.03 | 30 (30.61%) |
2 | Daiwa Pharmaceutical Co. Ltd. | Japan | Commercial | 2000 – 2017 | 10 | 10.64 | 11 (11.22%) |
3 | University of California at Irvine | USA | Academic | 2003 - 2021 | 3 | 9.00 | 9 (9.18%) |
3 | University of Mansoura | Egypt | Academic | 2008 – 2020 | 5 | 13.12 | 9 (9.18%) |
5 | Erom Co. Ltd. | South Korea | Commercial | 2004 – 2022 | 13 | 15.49 | 8 (8.16%) |
6 | Chiba University | Japan | Academic | 2000 - 2017 | 12 | 14.49 | 7 (7.14%) |
7 | University of Pécs | Hungary | Academic | 2013 – 2018 | 12 | 14.36 | 7 (7.14%) |
8 | University of Miami Miller School of Medicine | USA | Academic | 2013 - 2022 | 21 | 10.59 | 4 (4.08%) |
# | Publications | IF | Cite Score | Publisher | Quartile: Category | Art Count (% Total) | Publishing Period |
---|---|---|---|---|---|---|---|
1 | Clinical Pharmacology and Therapy (Yakuri to Rinsho) | NA | NA | Iyaku Shuppan | NA | 6 (6.12%) | 2004 - 2004 |
2 | International Journal of Immunopathology and Pharmacology | 3.219 | 4.1 | Sage Publications | Q1: Medicine (all) | 5 (5.10%) | 2004 - 2016 |
3 | Anticancer Research | 2.48 | 3.8 | International Institute of Anticancer Research | Q3: Cancer Research; Q3: Oncology | 4 (4.08%) | 2005 - 2014 |
4 | Evidence-based Complementary and Alternative Medicine | 2.629 | 3.0 | Hindawi Publishing | Q1: CAM | 3 (3.06%) | 2014 - 2020 |
4 | Journal of the Korean Society of Food Science and Nutrition | 0.548 | 0.9 | The Korean Society of Food Science and Nutrition | Q3: Food Science; Q4: Nutrition & Dietetic | 3 (3.06%) | 2004 - 2022 |
5 | Biomedicine & Pharmacotherapy | 6.529 | 9.3 | Elsevier | Q1: Pharmacology | 2 (2.04%) | 2020 - 2020 |
5 | Cancer Detection and Prevention (Continued as Cancer Epidemiology from 2009) | 2.984 | 3.9 | Elsevier | Q3: Cancer Research; Q3: Epidemiology; Q3 – Oncology | 2 (2.04%) | 2000 - 2008 |
5 | Cancer Letters | 8.679 | 14 | Elsevier | Q1: Cancer Research: Q1: Oncology | 2 (2.04%) | 2003 - 2008 |
5 | Clinical Case Reports and Reviews | NA | NA | Open Access Text | NA | 2 (2.04%) | 2015 - 2016 |
5 | Integrative Cancer Therapies | 3.279 | 4.0 | Sage Publications | Q1: CAM; Q2: Oncology | 2 (2.04%) | 2016 – 2016 |
5 | International Congress on Anti-Aging & Biomedical Technologies | NA | NA | American Academy of Anti-Aging Medicine | NA | 2 (2.04%) | 1999 - 2000 |
5 | Journal of Agricultural and Food Chemistry | 5.279 | 7.3 | ACS Publications | Q1: Agricultural & Biological Sciences (all): Q1: Chemistry (all) | 2 (2.04%) | 2013 - 2014 |
5 | Journal of Dietary Supplements | 2.272 | 3.9 | Informa Healthcare | Q2: Food Science: Q2: Nutrition & Dietetic; Q2: Pharmacology | 2 (2.04%) | 2008 - 2020 |
5 | Journal of Japanese Association for Dietary Fiber Research | NA | NA | Japanese Association for Dietary Fiber Research | NA | 2 (2.04%) | 2001 - 2002 |
5 | Journal of Radiation Research | 2.724 | 3.5 | Oxford Academic | Q2:HTM; Q2: RadiationQ2: Radiology, Nuclear Medicine and Imaging | 2 (2.04%) | 2013 - 2019 |
5 | Neoplasma | 2.757 | 3.3 | AEPress | Q1: Medicine (all); Q3: Oncology | 2 (2.04%) | 2009 - 2011 |
5 | Nutrition and Cancer | 2.9 | 4.1 | Routledge | Q3: Cancer Research; Q2: Medicine (misc); Q2: Nutrition & Dietetic; Q2: Oncology | 2 (2.04%) | 2008 - 2016 |
Ranking By: | Article | Publication | Study Design | Year | Citations: | ||
---|---|---|---|---|---|---|---|
Others | Others | ||||||
1 | 1 | Ghoneum (1998b) | International Journal of Immunotherapy | Before & after | 1998 | 180 | 59 |
2 | 2 | Ghoneum (1998a) | Biochemical and Biophysical Research Communications | Cell | 1998 | 146 | 44 |
3 | 3 | Ghoneum & Jewett (2000) | Cancer Detection and Prevention | Cell | 2000 | 132 | 35 |
4 | 6 | Ghoneum & Matsuura (2004) | International Journal of Immunopathology and Pharmacology | Cell | 2004 | 124 | 25 |
5 | 4 | Ghoneum & Abedi (2004) | Journal of Pharmacy and Pharmacology | Animal + Cell | 2004 | 100 | 29 |
6 | 9 | Noaman et al. (2008) | Cancer Letters | Animal | 2008 | 98 | 18 |
7 | 5 | Ghoneum & Gollapudi (2003) | Cancer Letters | Cell | 2003 | 93 | 27 |
8 | - | Kim H.Y. et al. (2007) | Journal of Medicinal Food | Animal | 2007 | 85 | 5 |
9 | - | Pérez-Martínez et al. (2015) | Cytotherapy | Animal + Cell | 2015 | 73 | 12 |
10 | 9 | Badr El-Din et al. (2008) | Nutrition and Cancer | Animal | 2008 | 69 | 18 |
- | 6 | Ghoneum & Brown (1999) | Anti-aging Medical Therapeutics | Before & after | 1999 | 61 | 25 |
- | 9 | Ghoneum & Agrawal (2011) | International Journal of Immunopathology and Pharmacology | Cell | 2011 | 60 | 18 |
- | 8 | Jacoby et al. (2001) | Journal of Nutraceuticals, Functional & Medical Foods | Animal | 2001 | 41 | 19 |
Context | Method | Intervention | Outcome |
---|---|---|---|
Humans (59) Animals (43) Male (32) Female (27) Aged (14) Middle Aged (11) Adult (9) Neoplasms (9) |
Mice (29) Liver (15) Rats (14) Lipopolysaccharides (10) Spleen (9) Enzyme-Linked Immunosorbent Assay (9) Cell Line (8) Cell Line, Tumor (8) Rats, Wistar (6) |
Polysaccharide MGN3 (62) Arabinoxylan (59) Xylans (39) Oryza (25) Shiitake Mushrooms (19) Immunologic Factors (15) Dietary Supplements (12) Hemicellulose (11) Polysaccharides (11) Water (11) Antineoplastic Agents (10) Injections, Intraperitoneal (9) Antioxidants (7) Adjuvants, Immunologic (6) Dose-Response Relationship, Drug (6) Hydrolysis (6) |
Killer Cells, Natural (30) Cytokines (21) Macrophages (16) Quality of Life (15) Apoptosis (12) Cell Proliferation (10) Body Weight (9) Inflammation (9) Interferons (9) Tumour Necrosis Factor-alpha (9) Biomarkers (8) Interleukin-6 (7) T-Lymphocytes (7) Transaminases (7) Up-Regulation (7) Gene Expression (6) Interferon-gamma (6) Lymphocytes (6) Oxidative Stress (6) Phagocytosis (6) |
# | Condition | Count (%) | Preclinical (%) | Observational (%) | Interventional (%) |
---|---|---|---|---|---|
1 | Cancer | 45 (45.92%) | 20 (44.44%) | 12 (26.67%) | 13 (28.89%) |
2 | Healthy / Nonspecific | 31 (31.63%) | 28 (90.32%) | - | 3 (9.68%) |
3 | Hepatitis / Liver Disease | 9 (9.18%) | 7 (77.78%) | - | 2 (22.22%) |
4 | Geriatric | 6 (6.12%) | 2 (33.33%) | - | 4 (66.67%) |
5 | HIV / AIDS | 4 (4.08%) | 1 (25%) | - | 3 (75%) |
6 | Allergy | 4 (4.08%) | 4 (100%) | - | - |
7 | CFS | 3 (3.06%) | - | - | 3 (100%) |
8 | Gastroenteritis | 3 (3.06%) | 2 (66.67%) | - | 1 (33.33%) |
9 | Cold / Flu | 2 (2.04%) | - | - | 2 (100%) |
10 | Diabetes mellitus | 2 (2.04%) | 2 (100%) | - | - |
11 | Endotoxemia | 2 (2.04%) | 2 (100%) | - | - |
12 | Chemical exposure | 1 (1.02%) | - | - | 1 (100%) |
13 | IBS | 1 (1.02%) | - | - | 1 (100%) |
14 | Rheumatism | 1 (1.02%) | - | 1 (100%) | - |
15 | Alzheimer's disease | 1 (1.02%) | 1 (100%) | - | - |
16 | Bacterial infection | 1 (1.02%) | 1 (100%) | - | - |
17 | Oxidative stress | 1 (1.02%) | 1 (100%) | - | - |
# | Beneficial Actions | Count (%) | Preclinical (%) | Observational (%) | Interventional (%) |
---|---|---|---|---|---|
1 | Immunomodulation | 36 (36.73%) | 21 (58.33%) | 1 (2.78%) | 14 (38.89%) |
2 | Synergistic anticancer effect | 19 (19.39%) | 7 (36.84%) | 10 (52.63%) | 2 (10.53%) |
3 | Hepatoprotection | 13 (13.27%) | 10 (76.92%) | 1 (7.69%) | 2 (15.38%) |
4 | Anticancer | 10 (10.20%) | 9 (90%) | 1 (10%) | - |
5 | Psychoneuroimmuno-modulation | 8 (8.16%) | - | 2 (25%) | 6 (75%) |
6 | Antiinflammation | 8 (8.16%) | 7 (87.50%) | 1 (12.5%) | - |
7 | Antioxidant | 7 (7.14%) | 7 (100%) | - | - |
8 | Radioprotection | 3 (3.06%) | 2 (66.67%) | - | 1 (33.33%) |
9 | Chemoprevention | 3 (3.06%) | 3 (100%) | - | - |
10 | Antiallergy | 3 (3.06%) | 3 (100%) | - | - |
11 | Antibacterial | 3 (3.06%) | 3 (100%) | - | - |
12 | Antifatigue | 2 (2.04%) | - | - | 2 (100%) |
13 | Antiflu | 2 (2.04%) | - | - | 2 (100%) |
14 | No significant effect | 2 (2.04%) | - | - | 2 (100%) |
15 | Gastroprotection | 2 (2.04%) | 1 (50%) | - | 1 (50%) |
16 | Antihyperlipidemic effect | 2 (2.04%) | 2 (100%) | - | - |
Other benefits that have one count each: Antiangiogenesis; Antiasthma; Antihyperglycemic effect; Antimetastatic effect; Antiretroviral; Antiviral; Antirheumatic effect; Antiwasting; Chemoprotection; Endothelial improvement; Memory enhancer; Noncytotoxic, Taste influencer. |
# | Positive Outcomes | Count (%) | Preclinical (%) | Observational (%) | Interventional (%) |
---|---|---|---|---|---|
1 | Cytokines | 25 (25.51%) | 19 (76%) | - | 6 (24%) |
2 | Cancer Proliferation | 21 (21.43%) | 14 (66.67%) | 7 (33.33%) | - |
3 | Safety & Adverse Events | 19 (19.39%) | 4 (21.05%) | 1 (5.26%) | 14 (73.68%) |
4 | Natural Killer Cells | 19 (19.39%) | 9 (47.37%) | - | 10 (52.63%) |
5 | Treatment Response | 19 (19.39%) | 1 (5.26%) | 9 (47.37%) | 9 (47.37%) |
6 | Survival Rate | 19 (19.39%) | 9 (47.37%) | 8 (42.11%) | 2 (10.53%) |
7 | Liver Function Markers | 18 (18.37%) | 12 (66.67%) | 2 (11.11%) | 4 (22.22%) |
8 | QoL Assessment | 15 (15.31%) | - | 8 (53.33%) | 7 (46.67%) |
9 | Inflammatory Markers | 13 (13.27%) | 10 (76.92%) | 1 (7.69%) | 2 (15.38%) |
10 | Macrophages | 13 (13.27%) | 13 (100%) | - | - |
11 | T & B Cells Proliferation | 11 (11.22%) | 8 (72.73%) | - | 3 (27.27%) |
12 | Gene Expression | 11 (11.22%) | 10 (90.91%) | - | 1 (9.09%) |
13 | Apoptosis | 11 (11.22%) | 11 (100%) | - | - |
14 | Lymphocytes | 9 ((9.18%) | 5 (55.56%) | - | 4 (44.44%) |
15 | Tumour Markers | 8 (8.16%) | - | 6 (75%) | 2 (25%) |
16 | Chemo Side Effects | 6 (6.12%) | 2 (33.33%) | 1 (16.67%) | 3 (50%) |
17 | Oxidative Stress Markers | 6 (6.12%) | 6 (100%) | - | - |
Other positive outcome measures: Incidence Rate (5), Dendritic Cells (5), Nitric Oxide Production (5), Mast Cells (3), Neutrophils (2), Histamine (2), Immunoglobulins (2), Eosinophils (1), Hematopoietic Tissues (1). |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 MDPI (Basel, Switzerland) unless otherwise stated